Pharvaris, N.V (PHVS)
| Market Cap | 644.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.93M |
| Shares Out | 33.15M |
| EPS (ttm) | -1.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,092 |
| Open | 18.75 |
| Previous Close | 19.00 |
| Day's Range | 18.31 - 19.44 |
| 52-Week Range | 13.14 - 27.50 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 40.46 (+108.1%) |
| Earnings Date | Aug 19, 2022 |
About PHVS
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 cli... [Read more...]
Analyst Forecast
According to 12 analysts, the average rating for PHVS stock is "Buy." The 12-month stock price forecast is 40.46, which is an increase of 108.13% from the latest price.
News
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference
ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...
Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...
Pharvaris Participates in the Kinin 2022 Conference
Pharvaris' tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite symposium Pharvaris' tailored drug development app...
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)
ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building...
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building...
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights
ZUG, Switzerland, May 11, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building...
Pharvaris to Participate in BofA Securities 2022 Healthcare Conference
ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildin...
Pharvaris to Participate in Upcoming April Investor Conferences
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildi...
Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
ZUG, Switzerland, March 29, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, buildi...
Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharm...
Data demonstrate PHA121 to be a potent human bradykinin B2 receptor antagonist Data demonstrate PHA121 to be a potent human bradykinin B2 receptor antagonist
Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference
ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Announces Changes to its Board of Directors
ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights
ZUG, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris to Participate in Upcoming September Investor Conferences
ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists ...
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
ZUG, Switzerland, July 30, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the...
Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE Multiple doses of PHA121 were well-tolerated and showed a favorable pharmaco...
Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of H...
ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists f...
Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights
ZUG, Switzerland, May 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists fo...
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...
Pharvaris to Participate in BioCapital Europe
ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the ...
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the t...
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI ...
Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers
Pharvaris Announces Closing of Initial Public Offering
ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization o...